1. Home
  2. ANL vs KEEL Comparison

ANL vs KEEL Comparison

Compare ANL & KEEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

SELL

Current Price

$10.00

Market Cap

998.8M

Sector

N/A

ML Signal

SELL

Logo Keel Infrastructure Corp. Common Stock

KEEL

Keel Infrastructure Corp. Common Stock

HOLD

Current Price

$1.73

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANL
KEEL
Founded
2004
2017
Country
Singapore
United States
Employees
N/A
274
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
1.1B
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
ANL
KEEL
Price
$10.00
$1.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
12
Target Price
★ $29.50
$5.23
AVG Volume (30 Days)
229.1K
★ 23.0M
Earning Date
08-14-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $229,276,000.00
Revenue This Year
$243.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 72.03
52 Week Low
$0.88
$1.61
52 Week High
$17.25
$7.37

Technical Indicators

Market Signals
Indicator
ANL
KEEL
Relative Strength Index (RSI) 41.78 34.86
Support Level $8.95 $1.61
Resistance Level $11.75 $3.91
Average True Range (ATR) 1.03 0.20
MACD 0.20 0.02
Stochastic Oscillator 42.35 14.55

Price Performance

Historical Comparison
ANL
KEEL

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About KEEL Keel Infrastructure Corp. Common Stock

Keel Infrastructure Corp is a North American digital infrastructure and energy company that develops and owns data centers and energy infrastructure for high-performance computing workloads, including AI. The group has a pipeline of 2.2 gigawatts and established grid interconnections already in place. It delivers scalable infrastructure solutions in high-demand power markets across Pennsylvania and Washington in the United States, and Quebec in Canada. It has data campuses in Moses Lake, Panther Creek, Sharon, Sherbrooke, and Scrubgrass.

Share on Social Networks: